Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ackman’s Pershing Square Funds Down Between 1.1-2% for 2011

PERSHING SQUARE“The three funds run by Bill Ackman’s Pershing Square Capital Management L.P. posted gains in December but still reported losses between 1.1% and 2% for the year, according to investor letters,” reports MarketWatch. “The performance numbers are net of fees.”

Pershing Square’s flagship fund, which manages approximately $4.3 billion in assets, performed best of the three. It gained a net 3.1% in December and finished the year down 1.1%. The Pershing Square International fund has $6 billion in assets under management. It gained marginally less than the flagship fund during the month of December, netting a 3% return, but its 2011 performance was the worst of the Pershing Square’s three funds, with a -2% return. Pershing Square II, which has just $82.9 million in assets under management, gained 3.1% in December to finish 2011 with a total return of -1.4%. In comparison, the S&P 500 had a total return of 2.1% in 2011, including dividend payments.

According to MarketWatch, “The firm didn’t mention any specific companies but said 78% of the fund’s investments were in companies with a market capitalization of more than $5 billion, and 14% were in midcaps between $1 billion and $5 billion.”

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!